Literature DB >> 18638570

The role of sphingosine kinase 1 in cancer: oncogene or non-oncogene addiction?

Mathew Vadas1, Pu Xia, Geoff McCaughan, Jennifer Gamble.   

Abstract

Sphingosine kinase 1 (SphK1) is a lipid kinase that catalyses the phosphorylation of sphingosine to sphingosine-1-phosphate. There is strong evidence from cellular or animal systems that SphK1 is involved in the major mechanisms underpinning oncogenesis, namely, the promotion of cellular survival, proliferation and transformation, the prevention of apoptosis and the stimulation of angiogenesis. Furthermore there is also good evidence from clinical samples that SphK1 is overexpressed in many, if not most tumor types examined and that many inhibitors of SphK1 render tumors sensitive to chemotherapeutic agents. A major question that remains concerns the exact mechanism of action of SphK1 in cancer. The tools available to probe SphK1 function perturb a set of cellular functions, and it is possible that several of these are involved in driving its oncogenic role. Furthermore, the importance of SphK1 functions in normal physiology and the lack of mutations of SphK1 in cancer, suggest that the mechanism in cancer might be an over reliance on this system of cellular signaling; an example of non-oncogene addiction.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18638570     DOI: 10.1016/j.bbalip.2008.06.007

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  70 in total

1.  The sphingosine kinase 1 inhibitor 2-(p-hydroxyanilino)-4-(p-chlorophenyl)thiazole induces proteasomal degradation of sphingosine kinase 1 in mammalian cells.

Authors:  Carolyn Loveridge; Francesca Tonelli; Tamara Leclercq; Keng Gat Lim; Jaclyn S Long; Evgeny Berdyshev; Rothwelle J Tate; Viswanathan Natarajan; Stuart M Pitson; Nigel J Pyne; Susan Pyne
Journal:  J Biol Chem       Date:  2010-10-06       Impact factor: 5.157

2.  Ceramide production mediates cinobufotalin-induced growth inhibition and apoptosis in cultured hepatocellular carcinoma cells.

Authors:  Long Cheng; Yuan-Zheng Chen; Yi Peng; Nan Yi; Xin-Shi Gu; Yong Jin; Xu-Ming Bai
Journal:  Tumour Biol       Date:  2015-02-28

Review 3.  p53 and regulation of bioactive sphingolipids.

Authors:  Linda A Heffernan-Stroud; Lina M Obeid
Journal:  Adv Enzyme Regul       Date:  2010-10-28

4.  Role of sphingosine kinase-1 in paracrine/transcellular angiogenesis and lymphangiogenesis in vitro.

Authors:  Viviana Anelli; Christopher R Gault; Ashley J Snider; Lina M Obeid
Journal:  FASEB J       Date:  2010-03-24       Impact factor: 5.191

5.  Development of amidine-based sphingosine kinase 1 nanomolar inhibitors and reduction of sphingosine 1-phosphate in human leukemia cells.

Authors:  Andrew J Kennedy; Thomas P Mathews; Yugesh Kharel; Saundra D Field; Morgan L Moyer; James E East; Joseph D Houck; Kevin R Lynch; Timothy L Macdonald
Journal:  J Med Chem       Date:  2011-05-02       Impact factor: 7.446

Review 6.  Evolving concepts in cancer therapy through targeting sphingolipid metabolism.

Authors:  Jean-Philip Truman; Mónica García-Barros; Lina M Obeid; Yusuf A Hannun
Journal:  Biochim Biophys Acta       Date:  2013-12-30

7.  Sphingosine kinase 1 downregulation is required for adaptation to serine deprivation.

Authors:  Jean-Philip Truman; Christian F Ruiz; Magali Trayssac; Cungui Mao; Yusuf A Hannun; Lina M Obeid
Journal:  FASEB J       Date:  2021-02       Impact factor: 5.191

8.  Differential expression of S1P receptor subtypes in human bladder transitional cell carcinoma.

Authors:  A Palangi; N Shakhssalim; M Parvin; S Bayat; A Allameh
Journal:  Clin Transl Oncol       Date:  2019-02-02       Impact factor: 3.405

9.  Sphingosine kinase 2 promotes lipotoxicity in pancreatic β-cells and the progression of diabetes.

Authors:  Ziyu Song; Wei Wang; Ning Li; Sishan Yan; Kuan Rong; Tian Lan; Pu Xia
Journal:  FASEB J       Date:  2018-11-19       Impact factor: 5.191

Review 10.  Therapeutic potential of targeting sphingosine kinases and sphingosine 1-phosphate in hematological malignancies.

Authors:  C Evangelisti; C Evangelisti; F Buontempo; A Lonetti; E Orsini; F Chiarini; J T Barata; S Pyne; N J Pyne; A M Martelli
Journal:  Leukemia       Date:  2016-07-27       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.